TY - JOUR
KW - Adult
KW - Animals
KW - Anti-Bacterial Agents
KW - Aza Compounds
KW - Fluoroquinolones
KW - Foot
KW - Humans
KW - leprosy
KW - Male
KW - Mice
KW - Middle Aged
KW - Moxifloxacin
KW - Mycobacterium leprae
KW - Quinolines
KW - Skin
KW - Treatment Outcome
AU - Pardillo FE
AU - Burgos J
AU - Fajardo TT
AU - Dela Cruz E
AU - Abalos R
AU - Paredes RM
AU - Andaya CE
AU - Gelber R
AB - <p>In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P <or= 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.</p>
BT - Antimicrobial agents and chemotherapy
C1 - http://www.ncbi.nlm.nih.gov/pubmed/18573938?dopt=Abstract
DA - 2008 Sep
DO - 10.1128/AAC.01162-07
IS - 9
J2 - Antimicrob. Agents Chemother.
LA - eng
N2 - <p>In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P <or= 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.</p>
PY - 2008
SP - 3113
EP - 7
T2 - Antimicrobial agents and chemotherapy
TI - Powerful bactericidal activity of moxifloxacin in human leprosy.
UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533472/pdf/1162-07.pdf
VL - 52
SN - 1098-6596
ER -